Skip to main content

sec filings

Insider trades

Open-market buys and sales that company insiders report to the SEC on .

Side
Planned sales
Role
ATTO

Updated 10/6/2026, 11:12 AM ET.

ATTO

Attovia Therapeutics, Inc.

Sale$2,251,658

WALSH COLIN

Director

105,807 shat $21.28Filed Aug 28, 5:38 PM ET
Amended
Filing
ATTO

Attovia Therapeutics, Inc.

Buy$10,285,000

WALSH COLIN

Director

585,000 shat $17.58Filed Aug 28, 5:38 PM ET
Amended
Filing
ATTO

Attovia Therapeutics, Inc.

Sale$2,251,658

GOLDMAN SACHS GROUP INC

Insider

and 7 others

105,807 shat $21.28Filed Aug 28, 5:38 PM ET
Amended
Filing
ATTO

Attovia Therapeutics, Inc.

Buy$10,285,000

GOLDMAN SACHS GROUP INC

Insider

and 7 others

585,000 shat $17.58Filed Aug 28, 5:38 PM ET
Amended
Filing
ATTO

Attovia Therapeutics, Inc.

Sale$2,251,658

WALSH COLIN

Director

105,807 shat $21.28Filed Aug 13, 9:52 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Buy$10,285,000

WALSH COLIN

Director

585,000 shat $17.58Filed Aug 13, 9:52 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Sale$2,251,658

GOLDMAN SACHS GROUP INC

Insider

and 7 others

105,807 shat $21.28Filed Aug 13, 9:51 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Buy$10,285,000

GOLDMAN SACHS GROUP INC

Insider

and 7 others

585,000 shat $17.58Filed Aug 13, 9:51 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Buy$6,499,984

venBio Global Strategic Fund IV, L.P.

10% owner

382,352 shat $17.00Filed Aug 10, 4:12 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Buy$10,200,000

Redmile Group, LLC

10% owner

and 2 others

600,000 shat $17.00Filed Aug 7, 9:47 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Buy$5,100,000

Sanofi

10% owner

300,000 shat $17.00Filed Aug 7, 3:45 PM ETFiling
ATTO

Attovia Therapeutics, Inc.

Buy$9,999,995

Frazier Life Sciences XI, L.P.

10% owner

and 2 others

588,235 shat $17.00Filed Aug 6, 5:35 PM ETFiling

Read from public SEC filings. Not financial advice.